What’s ADC drug?
The ADC, known as Anti-Puppets (Antibody Drug Conjugate), is an innovative biotechnological drug that has received extensive attention in recent years in the field of oncology treatment. The drug consists of a single clone of antibody, a hysterectonic bridge and a cytotoxic molecule. The monoclonic antibodies function to identify specific proteins of tumour cells so that they can be accurately targeted and attached to the cancer cell surface. The cytotoxic molecule is the killing factor for the cancer cell. When a single cloned antibody reaches its target position, it triggers a connection to a tumour cell, thus releasing a cell-toxic molecule to kill a cancer cell. The ADC drug has the advantage of its precision and robust treatment effectiveness. The precise impact characteristics of the drug can minimize damage to normal cells, thus reducing the side effects of the drug and improving its efficacy. And it’s precisely because of this particular target-oriented effect that ADC drugs are treated with less treatment pressure than traditional drugs. **HER2 Positive breast cancer patients can use ADC drugs? ** For HeR2 positive breast cancer patients, ADC drug is a very interesting treatment option. HeR2-positive breast cancer is a more serious breast disease and poses a major challenge to the effective treatment of such patients, especially those in the late stages where the tumour condition is developing more rapidly. In recent years, ADC drugs for Sher2-positive breast cancer, such as Patto Joll, have been introduced into the market, giving new hope to such patients. These drugs are specific to the cancer cells that can be identified and act on overexpressed HER2 receptors and effectively control the growth and spread of tumours. In addition, clinical data attest to the good efficacy and safety of ADC drugs in HeR2-positive breast cancer patients. When ADC drugs are used, doctors develop individualized treatment programmes based on the patient ‘ s specific circumstances. This includes the dose of the drug, the way it is delivered and the combination of other treatments. Through comprehensive treatment, many Her2-positive breast cancer patients are effectively controlled and their quality of life has improved significantly. Of course, in the use of ADC drugs, patients also need to follow their physical condition closely and conduct periodic reviews and evaluations. It was also important to maintain good communication with doctors in order to adapt treatment programmes in a timely manner and to deal with possible problems. In conclusion, the ADC drug is an effective treatment option for HeR2-positive breast cancer patients as a new tumour treatment. By accurately combating cancer cells, reducing damage to normal cells and combining traditional treatments, we can provide safer and more effective treatments for such patients. The specific circumstances of each patient are, of course, unique, and it is therefore necessary to consult with and follow the advice of a specialist prior to the use of any drug.
